Tempus AI, a pioneer in precision medicine and artificial intelligence, has extended its partnership with Remix Therapeutics, a clinical-stage biotechnology company that specializes in the development of small molecule therapies that regulate RNA processing. The partnership, which initiated with the licensing of specific de-identified data cohorts, has since expanded into a more comprehensive strategic alliance.
The expanded collaboration will advance Remix Therapeutics' Phase I trial for REM-422, a potent and selective oral small molecule messenger RNA degrader. In order to facilitate their research, Remix is employing Tempus xT and xR assays to acquire comprehensive DNA and RNA data. Furthermore, the xM Monitor, a circulating tumor DNA assay from Tempus, is currently being employed on an exploratory basis to monitor the response to treatment by detecting changes in circulating tumor fractions in patients with advanced malignancies.
Ryan Fukushima, Chief Operating Officer of Tempus, commented on the collaboration, stating “We’re excited to work with a biotech like Remix that understands and embraces the value that Tempus’ multimodal data can bring to their important work”. Remix Therapeutics is forging ahead in the development of innovative RNA-targeted therapies, while Tempus continues to advance precision medicine with its AI-driven solutions and cutting-edge technology.
